Category Archives: Global News Feed

23% (6/26) of patients with RAS/MAPK-altered non-CRC solid tumors and 44% (4/9) with BRAF-driven non-CRC solid tumors responded (confirmed and unconfirmed PR) to single agent ERAS-007 or ERAS-601

Here is the original post:
Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future...

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 10:15 a.m. ET.

More here:
Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference

TUSTIN, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference. Nick Green, president and chief executive officer of Avid Bioservices, will be the featured speaker in a fireside chat at the conference, which will take place September 12-14, 2022, in New York City.

Go here to read the rest:
Avid Bioservices to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

Montrouge, France, September 7, 2022

Read the rest here:
DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7...

BUFFALO, N.Y., Sept. 07, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced changes in its management team as the Company accelerates growth in its reduced nicotine content tobacco business. The Company announced that Michael Zercher, President and Chief Operating Officer, will depart the Company effective September 30, 2022. John Miller, who leads 22nd Century’s tobacco business team, will assume the tobacco-related duties of the Chief Operating Officer’s role, while Chief Executive Officer James A. Mish will assume the title of Corporate President.

Read more from the original source:
22nd Century Group (Nasdaq: XXII) Announces Management Updates and Departure of Chief Operating Officer

David Grand has Resigned as CEO and Chairman of the Company Effective Immediately to Pursue a New Role Involving Boundary Bay Cannabis and Other Corporate Development Initiatives David Grand has Resigned as CEO and Chairman of the Company Effective Immediately to Pursue a New Role Involving Boundary Bay Cannabis and Other Corporate Development Initiatives

The rest is here:
Agra Ventures Appoints Nick Kuzyk as Interim Chief Executive Officer

SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022.

Visit link:
Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that The New England Journal of Medicine (NEJM) has published a second manuscript detailing positive results from the company’s two-part Phase 2 LILAC study, which evaluated litifilimab (also known as BIIB059), an investigational drug, in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Results from the SLE portion of the study (Part A) published today show litifilimab met the study’s primary endpoint by significantly reducing total active joint count compared to placebo. Positive data from the CLE portion of the study were published in NEJM on July 28th, 2022.

Read more:
The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus

Top-line findings will be presented Sept. 10 at the annual European Society for Medical Oncology (ESMO) Congress

See more here:
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in...

- Presentation at World ADC Conference in San Diego -

Visit link:
CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting...